Botox for Chronic Migraine: when it is more than “just a headache”

Most people still think of Botox as an aesthetic treatment first.

That is understandable. It is one of the few medicines whose public identity was shaped by beauty before most people ever heard about its clinical uses.

But chronic migraine changes the tone of that conversation very quickly.

When headache starts to organise your month for you — when mornings feel uncertain before they have properly begun, when plans are made provisionally, when work and concentration are repeatedly negotiated around symptoms — the question is no longer whether you “get headaches”.

The question is whether you are dealing with a condition that has moved into a different category altogether.

That is where botulinum toxin (Botox) becomes relevant in a much more serious way.

In the UK, botulinum toxin type A has an established place in the prevention of chronic migraine.

Not general headache.

Not every pattern of “tension”.

Not casual forehead Botox repackaged with bigger promises.

Chronic migraine has a recognised treatment pathway, and Botox sits within it for the right patient, at the right stage, for the right reasons (NICE, 2025a; NICE, 2025b).

When headache stops being occasional

Chronic migraine has a formal definition, even if patients rarely describe it in formal language. It means headache on 15 or more days each month, with migraine features on at least 8 of those days, for more than 3 months.

In real life, though, it is usually recognised less by the definition than by its shape: the sense that symptoms are no longer interrupting life occasionally, but beginning to structure it (NICE, 2025a; NICE, 2025b).

That distinction matters because chronic migraine is not simply “bad headaches”. It is a neurological condition with a recognised preventive pathway. That is exactly why the conversation around treatment needs to be more precise than it often is online (NICE, 2025a; SIGN, 2023).

Not every “tension headache” is actually tension headache

This is one of the most important parts of the discussion, and one of the most commonly blurred.

Patients often say, understandably, that they “hold tension” in the neck, shoulders, temples or jaw, and from there conclude that the whole picture must be tension headache.

Sometimes it is.

Sometimes it is not.

NICE /evidence-based recommendations produced by the National Institute for Health and Care Excellence (NICE) in the UK/ describes tension-type headache as more typically pressing or tightening, often bilateral, usually mild to moderate, and not usually worsened by routine activity.

Migraine is more likely to be pulsating, more intense, and associated with symptoms such as nausea, photophobia or phonophobia (NICE, 2025b).

/Photophobia means sensitivity to light. Light feels unpleasant, painful, or makes symptoms worse. People often want to close their eyes, dim the room, or avoid bright daylight and screens.

Phonophobia means sensitivity to sound. Normal sounds may feel too loud, irritating, or even painful. People often want silence or a very quiet environment./

NICE also makes an important point: chronic migraine and chronic tension-type headache commonly overlap, and if there are any features of migraine, the diagnosis should be chronic migraine (NICE, 2025b).

That is why I would be careful with any source that talks loosely about Botox for “tension headaches” as though it were the same clinical conversation. The established indication is chronic migraine. That boundary does not make the treatment less interesting; it makes the discussion more honest.

What usually comes before Botox

This is the part many articles leave out, and this matters.

Botox is not usually the first step in migraine treatment. Long before it enters the conversation, most patients will already have moved through more conventional options.

For acute migraine, NICE recommends combination treatment with an oral triptan plus an NSAID, or an oral triptan plus paracetamol, depending on preference, comorbidities and risk of adverse effects. An anti-emetic may also be used, even when nausea is not the main complaint. NICE also advises against using ergots or opioids for the acute treatment of migraine (NICE, 2025b).

When attacks are frequent, disabling, or acute medicines are being used too often, the conversation usually shifts from aborting attacks to prevention.

The Migraine Trust notes that preventive treatment is often considered when migraine is having a major impact on daily life, when acute treatment is not helping enough, or when acute medicines are being used on more than two days a week (The Migraine Trust, 2025b).

In current NICE guidance, the main medicines considered for migraine prevention are propranolol, topiramate and amitriptyline. These are not interchangeable in a simplistic sense.

Choice depends on the person in front of prescriber: their other health conditions, other medicines, side-effect profile, pregnancy risk, and what is realistically tolerable and sustainable. NICE also highlights the particular safety issues around topiramate, including pregnancy and contraception considerations, and the need to discuss the risks and suitability of each option properly (NICE, 2025b).

In wider UK practice and specialist guidance, other preventive options may also appear in the pathway.

The Migraine Trust’s current preventive medicines factsheet lists drug classes and examples including beta-blockers such as propranolol, tricyclic antidepressants such as amitriptyline, anticonvulsants such as topiramate, and angiotensin II blockers such as candesartan.

Scottish guidance also recognises candesartan as a preventive option in some patients (The Migraine Trust, 2025b; SIGN, 2023).

Only once suitable preventive options have been tried and found ineffective, poorly tolerated, or unsuitable does the pathway move further. NICE’s current visual summary makes this very clear: after at least three preventive medicineshave failed, are not tolerated, or are unsuitable due to safety concerns, specialist options come into play.

For adults with chronic migraine, these include botulinum toxin type A (Botox). Depending on the broader clinical picture, NICE also now includes newer CGRP-targeting treatments such as erenumab, fremanezumab, galcanezumab, eptinezumab and atogepant within specialist preventive pathways (NICE, 2025c; NICE, 2024).

That is the real context for Botox. Not a beauty-adjacent shortcut.

A later-line, specialist preventive treatment sitting inside a much broader migraine pathway.

Why Botox entered the migraine conversation at all

Botox is often described far too simply, as though it helps migraine just by relaxing muscles. The current understanding is more interesting than that.

The Migraine Trust explains that Botox is thought to work by blocking neurotransmitters released from nerves, reducing the pain signals involved in migraine.

Mechanistic work also suggests that botulinum toxin reduces the release of pain-related mediators such as CGRP, substance P and glutamate, helping to reduce peripheral sensitisation and the burden of pain signalling (The Migraine Trust, 2025a; Burstein et al., 2020).

In simpler terms, this is not best understood as a wrinkle treatment that happens to help headaches. It is better understood as a preventive neurological treatment that happens to use a medicine people already know from aesthetics (The Migraine Trust, 2025a).

Why migraine Botox is not the same as cosmetic Botox

This distinction matters more than many people realise.

Botox for chronic migraine is not the same treatment as cosmetic anti-wrinkle Botox.

The dose is different.

The injection pattern is different.

The objective is different.

The current UK product information and migraine guidance describe treatment according to the recognised PREEMPT protocol, typically using 155 to 195 units delivered as 31 to 39 injections, usually every 12 weeks (AbbVie, 2025; The Migraine Trust, 2025a).

The usual treatment areas include the forehead, temples, back of the head, neck and shoulders. That is a medical protocol with a specific purpose. It should not be confused with a routine aesthetic treatment simply because the product name is the same (AbbVie, 2025; University Hospitals Sussex NHS Foundation Trust, 2024).

Who this treatment is actually for

Botox is not positioned early or casually in the migraine pathway. In the UK, it is generally considered for adults with chronic migraine who have already tried at least three preventive treatments without adequate success, or who could not tolerate them, and where medication overuse has been appropriately addressed (NICE, 2025a; NICE, 2025c).

The Migraine Trust also notes that Botox for migraine it may be accessed through a headache specialist or consultant neurologist, rather than approached casually as a general headache treatment (The Migraine Trust, 2025a).

That may sound narrower than people expect, but it is part of what makes the pathway medically credible. Good care is not just about knowing a treatment exists. It is about knowing who genuinely fits the pathway for it.

What a serious consultation should clarify

This is where, in my view, a lot of online information becomes too shallow to be genuinely useful.

Before Botox is ever discussed properly, I would want to understand how many headache days you have each month, how many of those are clearly migraine days, what preventive medicines you have already tried, how often you are using painkillers or triptans, whether a headache diary has been kept, and whether there are overlapping factors such as jaw clenching, neck tension or trapezius pain that may be contributing without necessarily being the main diagnosis (NICE, 2025b).

NICE recommends that, if a headache diary is used, it should record frequency, duration, severity, associated symptoms, all prescribed and over-the-counter medication used, possible precipitants, and relation to menstruation, for a minimum of 8 weeks.

That is not bureaucracy.

It is one of the clearest ways of bringing structure to a symptom pattern that often feels chaotic to the person living with it (NICE, 2025b).

What patients should expect — and what they should not

Botox is not an instant rescue treatment for a migraine already underway.

It is a preventive treatment, and the response usually needs to be judged over time. Some people notice benefit early, but the pattern is often clearer after one or two treatment cycles rather than after a few days of scrutiny (The Migraine Trust, 2025a; The Migraine Trust, 2025b).

For many people, Botox reduces both the frequency and severity of migraine.

The Migraine Trust states that, for many patients, it reduces headache burden by around 30% to 50%. That may not sound dramatic to someone outside the condition, but for a patient living with 20 headache days a month, that reduction can change the practical shape of everyday life (The Migraine Trust, 2025a).

NICE guidance is also clear that treatment should not simply continue on reputation alone. It should be stopped if, after two treatment cycles, headache days have not reduced enough, defined as less than a 30% reduction in headache days per month (NICE, 2025a; NICE, 2025c).

Side effects deserve a proper mention too

A serious conversation about treatment should not hide side effects behind vague reassurance.

The current UK product information and patient resources describe recognised possibilities (rarely occuring) such as neck pain, muscular weakness or stiffness, injection-site discomfort, eyelid drooping, and sometimes a temporary worsening of migraineshortly after treatment (AbbVie, 2025; The Migraine Trust, 2025a).

That does not make the treatment unsafe when used properly.

It simply means it should be approached as a medical intervention, with correct diagnosis, appropriate patient selection, proper technique and realistic counselling from the beginning.

The point of good information is not hype

What chronic migraine often does to people is make them doubt the legitimacy of seeking a better explanation. They start minimising the pattern because they have been living inside it for so long.

That is part of why Botox interests people so much once they hear about it. Not because it sounds glamorous, but because it suggests the cycle itself might be interrupted.

Used in the right place, for the right patient, that is what makes it clinically worthwhile.

The important part, though, is not the familiarity of the name.

It is the accuracy of the diagnosis.

Before Botox is ever discussed properly, the more serious question is whether the pattern in front of me is truly chronic migraine — and whether you are far enough into the preventive pathway for Botox to be the right next step at all (NICE, 2025a; NICE, 2025b).

Frequently asked questions:

How do I know whether I have chronic migraine or tension headaches?

The distinction comes from the overall pattern, not from one symptom alone.

Chronic migraine means headache on 15 or more days a month, with migraine features on at least 8 of those days, for more than 3 months.

Tension-type headache is more often described as pressing or tightening, usually milder, and not typically worsened by normal activity, whereas migraine is more likely to be throbbing, more intense, and associated with nausea or light and sound sensitivity (NICE, 2025b).

Can someone have both migraine and tension-type headaches?

Yes. NICE specifically states that chronic migraine and chronic tension-type headache commonly overlap. If there are any features of migraine, the diagnosis should be chronic migraine, which is one reason why the history matters more than labels patients may already have been given (NICE, 2025b).

If my headaches start in my neck and shoulders, does that mean they are tension headaches rather than migraine?

Not necessarily. NICE’s diagnostic table makes it clear that pain in primary headache disorders can involve the head, face or neck, so location alone does not settle the diagnosis. Neck and shoulder pain can sit alongside migraine, contribute to how it is felt, or be part of a mixed picture — but they do not automatically mean the problem is “just tension” (NICE, 2025b).

Who is actually eligible for Botox for chronic migraine in the UK?

In the NHS, Botox is considered for adults with chronic migraine whose condition has not responded to at least three prior preventive treatments, or where those options have not been tolerated or are unsuitable, and where medication overuse has been appropriately addressed. It is not licensed for episodic migraine, tension-type headache, or cluster headache (NICE, 2025a; The Migraine Trust, 2025a).

Why do I need to have tried three preventive medicines first?

Because that is where Botox sits in the recognised treatment pathway: it is a later-line specialist preventive treatment, not a first-step option. In current UK guidance, preventive medicines commonly considered earlier include propranolol, topiramate and amitriptyline, with other options used in some patients depending on suitability and clinical context (NICE, 2025a; NICE, 2025b; The Migraine Trust, 2025b).

What counts as medication overuse?

A doctor may diagnose medication overuse headache if acute medicines have been taken too often for at least 3 months. The commonly used thresholds are 15 or more days a month for simple painkillers such as paracetamol or NSAIDs, and 10 or more days a month for triptans, opioids, ergotamine or combination painkillers (The Migraine Trust, 2025c).

Do I need to keep a headache diary before treatment?

It is strongly advisable, and in practice it is extremely helpful. NICE says that if a headache diary is used, it should record frequency, duration, severity, associated symptoms, medication use, possible triggers, and relation to menstruation for a minimum of 8 weeks. For Botox specifically, The Migraine Trust says a diary is usually used to help monitor whether treatment is working (NICE, 2025b; The Migraine Trust, 2025a).

Why are so many injections needed for migraine Botox?

Because migraine Botox follows a specific medical protocol, not a cosmetic treatment pattern. The PREEMPT protocol uses 31 up to 39 injections across the forehead, temple region, back of the head, neck and shoulders, targeting the main nerve-related pain regions involved in chronic migraine (AbbVie, 2025; The Migraine Trust, 2025a).

Will migraine Botox make my face look frozen?

That is not the aim of treatment. Migraine Botox is delivered according to a medical protocol rather than a cosmetic one, although some of the injection sites do include the forehead, so a degree of softening in movement can occur. The point of treatment is migraine prevention, not creating a cosmetic effect (AbbVie, 2025; The Migraine Trust, 2025a).

How long does it take to start working?

Some people notice improvement within the first couple of weeks, but Botox is not judged like an instant treatment. The Migraine Trust says that most people have at least two treatment cycles before deciding whether it is working properly, and some NHS patient information notes that the first set of injections may take around 10 to 14 days before improvement becomes noticeable (The Migraine Trust, 2025a; NHS Lothian, 2023).

What happens if the first cycle does not help much?

One disappointing first cycle does not automatically mean the treatment has failed. The Migraine Trust says most people have at least two treatment cycles before deciding whether Botox is working, and NICE uses a 30% reduction in headache days after two cycles as the key stopping threshold. If Botox is not helping enough, the next step is usually to review the diagnosis, the diary, and the wider preventive pathway rather than simply continuing indefinitely (The Migraine Trust, 2025a; NICE, 2025a).

What if I have migraine but also clench my jaw or carry a lot of tension in my neck and shoulders?

That does happen. Headache disorders can overlap, and muscular factors such as jaw clenching or neck and trapezius tension can complicate how symptoms are felt. The key point is that these contributors do not replace the need to decide whether the underlying diagnosis is still chronic migraine, because that is what determines whether the Botox migraine pathway is appropriate (NICE, 2025b).

If my headaches feel more like pressure than throbbing pain, does that change whether Botox is appropriate?

It may change how the diagnosis is approached, yes. A pressing or tightening quality leans more towards tension-type headache, whereas a pulsating quality with nausea or light and sound sensitivity is more typical of migraine — but no single symptom settles it on its own. Botox for migraine is appropriate when the overall pattern fits chronic migraine, not just because one individual headache feature is present or absent (NICE, 2025b).

Can jaw clenching, bruxism or trapezius tension make migraine worse even if they are not the main diagnosis?

They can certainly make the picture more uncomfortable and more complicated. In practice, patients may have migraine alongside jaw tension, bruxism or neck and shoulder overactivity, and those factors can add to pain burden without being the main diagnosis themselves. The important thing is not to let those contributors obscure the bigger question of whether the person still fits the pattern of chronic migraine (NICE, 2025b).

Written by Piotr Wojtowicz, MPharm, Independent Prescriber, MSc Cosmetic & Aesthetic Medicine, PGDip Dermatology

References

AbbVie Ltd (2025) BOTOX 100 Allergan Units Powder for solution for injection: Summary of Product Characteristics. Updated 14 May 2025. Available via the electronic Medicines Compendium.

Burstein, R., Noseda, R. and Borsook, D. (2020) Mechanism of action of onabotulinumtoxinA in chronic migraine. Mechanistic review discussing the effect of onabotulinumtoxinA on peripheral sensitisation and pain-related mediators in chronic migraine. Supported here alongside current patient-facing migraine resources.

NICE (2024) Atogepant for preventing migraine (TA973). Technology appraisal covering atogepant as an option after 3 or more preventive medicines.

NICE (2025a) Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260). Current NICE technology appraisal page. Originally published in 2012 and retained following later review.

NICE (2025b) Headaches in over 12s: diagnosis and management (CG150). NICE guideline page updated in 2025, including diagnostic features, acute treatment, preventive treatment, and headache diary recommendations.

NICE (2025c) CG150 visual summary on prophylactic treatment of migraine with or without aura. Current visual summary covering escalation after 3 preventive medicines and specialist options including botulinum toxin type A and CGRP-targeting therapies.

SIGN (2023) SIGN 155: Pharmacological management of migraine. Scottish Intercollegiate Guidelines Network update recognising additional preventive options including candesartan in selected patients.

The Migraine Trust (2025a) Botox injections for migraine factsheet. Last reviewed February 2025.

The Migraine Trust (2025b) Preventive medicines for migraine factsheet. Last reviewed January 2025.